Saturday, February 8, 2025

Cancer Treatment Advances: MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Agent

Similar articles

Cancer treatment is advancing with promising updates from MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies. MAIA recently announced positive treatment updates from its Phase 2 clinical trial, THIO-101, evaluating the novel treatment THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who have failed two or more standard-of-care therapy regimens.

The THIO-101 trial involves a therapeutic regimen cycled every 3 weeks. THIO is administered at 180mg in 60mg incremental doses on days 1, 2, and 3, followed by immune activation on day 4, with no dosing, and cemiplimab at 350mg on day 5.

Subscribe Weekly Market Access News

* indicates required

Cancer Treatment Advances: Six Patients Continue Long-Term Therapy with THIO and Cemiplimab

Six patients remain on treatment following at least 12 months of therapy. Treatment with THIO followed by cemiplimab has been well tolerated throughout the trial, showing much lower toxicity compared to standard-of-care treatments, demonstrating safety, efficacy, and ongoing benefit from MAIA’s novel telomere targeting NSCLC therapy.

Dr. Vlad Vitoc, Chairman and Chief Executive Officer of MAIA, expressed optimism regarding the trial outcomes: “Our longest-treated patient so far has completed 21 cycles of THIO sequenced with a CPI, and 6 patients who have crossed the 12-month survival follow-up are continuing the treatment. With current therapies, second-line patients’ treatment duration is usually around 3-4 months and third-line is even lower than that. It is very encouraging to see that our patients can remain on treatment for much longer. The ongoing benefits of THIO in longer-term patients are particularly notable, signifying THIO’s potential as a durable and efficacious treatment for advanced NSCLC patients faced with limited options.”

The data from the THIO-101 trial highlights the promising potential of THIO as part of a combined regimen with cemiplimab for patients with advanced NSCLC. Patients who had previously exhausted standard-of-care options now have a new avenue for treatment, offering hope for better outcomes and improved quality of life.

cancer

Cancer Breakthrough: THIO’s Unique Telomere-Targeting Mechanism Enhances Immune Response and Clinical Outcomes

The key advantage of THIO lies in its unique mechanism of action. THIO targets telomeres, which are protective caps at the ends of chromosomes that play a critical role in cellular aging and cancer progression. By targeting telomeres, THIO disrupts the replication process of cancer cells, making them more susceptible to immune system attack. When combined with cemiplimab, an immune checkpoint inhibitor, this approach can enhance the body’s immune response against cancer cells, potentially leading to better clinical outcomes.

The THIO-101 trial’s encouraging results suggest that THIO, in combination with cemiplimab, may offer a viable new treatment option for patients with advanced NSCLC who have limited choices after failing multiple lines of therapy. This novel approach could significantly impact the standard of care for this challenging and aggressive form of cancer.

MAIA Biotechnology’s commitment to advancing cancer treatment is further demonstrated by their rigorous clinical development program and their focus on innovative therapies that address unmet medical needs. The company’s dedication to improving patient outcomes is evident in the continued success of the THIO-101 trial and the potential of THIO to become a game-changing therapy in the fight against cancer.

As MAIA Biotechnology moves forward with the THIO-101 trial, they are focused on further validating the safety and efficacy of THIO in combination with cemiplimab. The company plans to continue monitoring patient outcomes, gathering additional data, and exploring the potential of this novel treatment regimen in broader patient populations.

You can follow our news on our Telegram, LinkedIn and Youtube accounts.

In conclusion, the latest updates from MAIA Biotechnology’s Phase 2 trial of THIO highlight significant progress in the development of innovative cancer treatments. The promising results underscore the potential of THIO as a durable and effective therapy for patients with advanced NSCLC, providing new hope for those facing limited treatment options. MAIA’s continued efforts to advance this therapy through rigorous clinical trials and collaboration with the medical community are poised to make a lasting impact on the landscape of cancer treatment.

 

Resource: Business Wire, July 23, 2024


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article